Autoimmune diseases - New insights into a troublesome field

Journal of Translational Autoimmunity

Urs Nydegger¹  Andreas Hemmerle²  Thomas Lung³  Benjamin Sakem³  Lorenz Risch³  Michèle Nydegger³  Martin Risch⁴ 

[1] Central Laboratory, Kantonsspital Graubünden, Chur, Switzerland;Corresponding author.;Center for Laboratory Medicine Dr Risch, Vaduz, Liechtenstein;Institute of Anesthesiology and Intensive Care Medicine, Triemli City Hospital, Zurich, Switzerland;

关键词: Innate immunity;    Cytokine;    Complement;    Monoclonal antibodies;    Biosimilars I;   

DOI  :  

来源: DOAJ

【 摘 要 】

Recent updates in the diagnosis and management of chronic inflammatory conditions can be brought together to better understand autoimmune diseases (ADs). With organ-specific or organ-limited and systemic ADs, physicians often are faced with a dilemma when making a diagnosis and may feel a kind of embarrassment when a more distinct nosological entity cannot be found. ADs often overlap with other diseases and good diagnostic procedures for ADs only become evidence-based when refined histopathologic, immunopathologic, and general laboratory analyses are available. Immunofluorescence analyses, Western blotting, CUT & RUN technology allow localization of the site of autoantibody-reactivity on the relevant DNA sequence. The Polymerase chain reaction technology and CRISPR-Cas9, the new gene editor using pools of synthetic non-coding RNAs in screening experiments, are expected to lead to advances in the diagnosis of ADs. The current use of mRNA as a vaccine against COVID-19 has increased confidence in the use of mRNA or long non-coding RNAs in the treatment strategy for ADs. The integration of new knowledge about innate immunity, the complement system, vaccinology, and senescence into the care of patients with ADs expands the therapeutic arsenal of disease-modifying drugs and allows for the repurposing of anti-cytokine monoclonal/biosimilar antibodies, originally designed for chronic inflammatory diseases, for ADs. This review article brings together some of the most relevant ideas; a case report included in this review highlights the difficulty of distinguishing between ADs, chronic inflammation, and/or granular disease.

【 授权许可】

Unknown